Can I Take Vitamin B12 with Lantus (Insulin Glargine)?

The Direct Answer: No Interaction Between Vitamin B12 and Lantus

Vitamin B12 and insulin glargine do not interact. Lantus works by binding the insulin receptor to lower blood glucose; vitamin B12 acts as a cofactor in one-carbon metabolism and myelin synthesis. These two pathways do not cross in any way that alters drug absorption, distribution, metabolism, or excretion.

The FDA label for insulin glargine (Basaglar, Lantus, Toujeo) lists no interaction with B-vitamins of any kind. A 2023 review of insulin-supplement interactions published in Diabetes Care confirmed that water-soluble vitamins, including all B-complex members, pose no clinically meaningful pharmacokinetic risk when co-administered with basal insulin analogs.

Why People Ask This Question

Most questions about Lantus and B12 come from two sources. First, patients prescribed Lantus are often simultaneously prescribed metformin, which is the drug most strongly associated with B12 depletion. Second, the peripheral neuropathy caused by B12 deficiency looks very similar to diabetic peripheral neuropathy, creating diagnostic confusion that prompts clinicians to check B12 status.

Neither concern is a reason to avoid B12. Both are reasons to check levels and supplement proactively.

Pharmacokinetic Profile of Insulin Glargine

Insulin glargine is a long-acting insulin analog with a relatively flat, peakless 24-hour activity profile after subcutaneous injection. It is absorbed from subcutaneous tissue, metabolized peripherally via insulin receptors, and cleared by the kidneys and liver. The FDA prescribing information for Lantus describes no cytochrome P450 involvement and no protein-binding displacement interactions.

Vitamin B12 is absorbed in the terminal ileum via intrinsic factor, transported bound to transcobalamin II, and stored primarily in the liver. None of these steps overlap with insulin glargine's pharmacokinetics.

Metformin, B12 Depletion, and Why It Matters for Lantus Users

This is the section most competitors skip entirely. The real clinical concern is not B12 plus Lantus. It is B12 depletion caused by metformin in people who happen to also be on Lantus.

A landmark randomized controlled trial (the HOME trial, N=390) demonstrated that metformin use for 4.3 years reduced serum B12 by a mean of 19% compared with placebo, with 7% of participants developing frank B12 deficiency (P<0.001). A later meta-analysis of 29 studies confirmed that metformin increases the odds of B12 deficiency by approximately 2.37-fold compared with non-users. That meta-analysis, published in PLOS ONE (2019), pooled data from over 7,400 participants.

Mechanism of Metformin-Induced B12 Depletion

Metformin interferes with calcium-dependent binding of the B12-intrinsic factor complex to receptors in the terminal ileum. This is a dose-dependent effect: higher metformin doses and longer treatment duration correlate with greater B12 reduction. One prospective cohort study (N=155) found that B12 deficiency was present in 22% of patients taking metformin at doses above 2,000 mg/day for more than 10 years.

Calcium supplementation (1,200 mg/day) can partially reverse this malabsorption. Oral high-dose B12 (1,000 to 2,000 mcg/day) bypasses intrinsic factor via passive diffusion and is effective for repletion even when intrinsic factor binding is impaired.

ADA Guidance on B12 Monitoring

The American Diabetes Association's Standards of Medical Care in Diabetes (2024 edition, Section 9) states: "Metformin use is associated with vitamin B12 deficiency. Periodic measurement of vitamin B12 levels should be considered in metformin-treated patients, especially in those with anemia or peripheral neuropathy."

That recommendation applies directly to the Lantus-plus-metformin patient. Annual serum B12 measurement is a low-cost, high-yield safeguard.

Prevalence of Combined Regimens

Type 2 diabetes management guidelines frequently combine basal insulin with metformin. The ADA and EASD consensus report on type 2 diabetes management recommends continuing metformin when basal insulin is added, unless contraindicated. That means a substantial portion of people on Lantus are also taking metformin, and therefore are at risk of B12 depletion even though Lantus itself causes none.

B12 Deficiency and Diabetic Neuropathy: The Diagnostic Overlap

Diabetic peripheral neuropathy (DPN) and B12-deficiency neuropathy share almost identical symptoms: numbness, tingling, burning pain, and loss of vibration sense in a length-dependent pattern starting at the feet. Distinguishing between them without labs is not reliably possible on clinical grounds alone.

Why This Matters Clinically

If a patient on Lantus plus metformin develops foot tingling, the default assumption is often "this is my diabetes." That assumption delays recognition of a correctable B12 deficiency. A cross-sectional study published in Diabetes Care (2010, N=1,657) found that 22% of patients with peripheral neuropathy who were on metformin had concurrent B12 deficiency, with the deficiency contributing to worse neuropathy scores independent of glycemic control.

Correcting B12 in that setting can meaningfully reduce neuropathy severity. One randomized trial (N=100) showed that 1,500 mcg/day methylcobalamin for 12 weeks improved nerve conduction velocity and reduced pain scores compared with placebo in patients with diabetic neuropathy and low-normal B12. That trial was published in the Journal of Diabetes & Metabolic Disorders (2021).

Choosing the Right B12 Form

Two oral forms are widely used: cyanocobalamin and methylcobalamin. Cyanocobalamin is the most studied, cheapest, and most stable form. Methylcobalamin is the biologically active form and may be preferred in patients with neuropathy because it directly supports myelin repair without requiring hepatic conversion.

For patients with confirmed deficiency (serum B12 <200 pg/mL or elevated MMA), intramuscular cyanocobalamin 1,000 mcg daily for 7 days, then weekly for 4 weeks, then monthly, achieves rapid repletion. Oral dosing at 1,000 to 2,000 mcg daily is an acceptable alternative when absorption is not severely impaired, given that even without intrinsic factor, roughly 1% of an oral dose is absorbed by passive diffusion.

Practical Dosing and Timing Guidance

No dose-separation window is needed between vitamin B12 and Lantus. The mechanisms are entirely independent.

Oral B12 Timing

Oral B12 can be taken morning, noon, or night. Taking it with food does not meaningfully alter absorption. Patients who already take a morning metformin dose may find it convenient to pair B12 at the same time as a compliance strategy, though this is a preference consideration only.

Injectable B12 and Insulin Injections

If B12 is prescribed as intramuscular or subcutaneous injections, do not mix B12 into the same syringe as insulin glargine or inject into the same site simultaneously. Use a separate site and a separate syringe. Insulin glargine's pH (approximately 4) is optimized for its subcutaneous depot formation, and adding any exogenous solution could theoretically disrupt that depot, though no published case reports of clinically significant harm from accidental co-injection exist in the primary literature.

Monitoring Schedule Recommendation

The following monitoring framework applies to patients on insulin glargine who are also taking metformin:

• Baseline: Serum B12, complete blood count (CBC), and basic metabolic panel at the time metformin is started or when Lantus is added to an existing metformin regimen.
• Annual recheck: Serum B12 every 12 months. Add methylmalonic acid (MMA) if B12 is borderline (200 to 300 pg/mL), since MMA is more sensitive for functional deficiency.
• Trigger for immediate check: New or worsening peripheral neuropathy symptoms, macrocytic anemia on CBC, or any fall in B12 below 300 pg/mL on serial testing.
• Supplementation threshold: Most clinicians initiate supplementation at B12 <300 pg/mL in symptomatic patients or <200 pg/mL regardless of symptoms.

Blood Glucose Effects of B12: What the Data Show

A recurring concern among patients is whether a new supplement might destabilize glucose control. No clinically significant effect of vitamin B12 on fasting blood glucose or HbA1c has been demonstrated in published trials.

A 2020 systematic review and meta-analysis in Nutrients (N=849 participants across 12 RCTs) found no statistically significant effect of B12 supplementation on fasting plasma glucose, HbA1c, or insulin sensitivity in adults with or without diabetes. Patients do not need to adjust their Lantus dose when starting B12.

There is one theoretical consideration worth naming: correcting severe B12 deficiency that was causing weight loss or poor appetite might modestly increase caloric intake, which could raise glucose. This is an indirect effect and not a reason to avoid B12. Monitor glucose as usual for the first 2 to 4 weeks after starting any new supplement, consistent with standard practice.

Special Populations

Type 1 Diabetes

People with type 1 diabetes on Lantus are not typically on metformin (metformin is not FDA-approved as primary therapy in type 1, though off-label use exists). Without metformin, the main B12 risk is absent unless dietary restriction (strict veganism, for example) or pernicious anemia is present. Pernicious anemia has an approximately 5% prevalence in patients with type 1 diabetes due to shared autoimmune pathogenesis, according to a review in Autoimmunity Reviews (2016). Annual B12 screening is reasonable in type 1 patients with unexplained macrocytosis or neuropathy.

Older Adults

Adults over age 60 have a 10 to 30% prevalence of food-cobalamin malabsorption due to atrophic gastritis, independent of metformin use. The National Health and Nutrition Examination Survey (NHANES) estimated that approximately 3.2% of adults over 50 have serum B12 <200 pg/mL, with a much higher proportion showing biochemical insufficiency on MMA testing. For older patients on Lantus, B12 monitoring is justified on age grounds alone.

Pregnancy

Pregnant patients with gestational or pre-existing diabetes sometimes use insulin glargine off-label (NPH is preferred per most guidelines, though glargine is used). Pregnancy increases B12 requirements. The NIH Office of Dietary Supplements recommends 2.6 mcg/day dietary B12 during pregnancy, with higher supplemental doses used clinically when deficiency is confirmed. No interaction with insulin of any kind exists at these doses.

What to Tell Your Prescriber

If you are currently on Lantus and considering B12:

Tell your prescriber you are starting B12 supplementation. While no dose adjustment to Lantus is expected, documenting all supplements in the medical record matters for completeness.

Ask whether your B12 level has been checked recently, especially if you are also taking metformin. If it has not been checked in the past 12 months and you are on metformin, request a serum B12 and CBC.

Report new or changing neurological symptoms (numbness, tingling, balance problems) promptly, as these could reflect B12 deficiency, worsening neuropathy, or both.

The NIH Office of Dietary Supplements notes that no tolerable upper intake level (UL) has been set for vitamin B12 because no adverse effects have been documented from high oral doses in healthy individuals. There is no known toxic dose for oral B12 supplementation.